The researchers found that the high level of FEZ1 expression in a specific laboratory rat cell line caused a significant block to retroviral infection - retroviruses were able to enter the host cells and synthesize the viral DNA, but were excluded from entering the host cell nucleus.
'We suspect that the overexpression of FEZ1 interferes with intracellular trafficking of the viral preintegration complex and traps the viral DNA in the cytoplasm. We hope that learning more about this transport machinery might reveal a new target for antiviral drugs in the treatment of HIV-1 disease.'
Contact: Heather Cosel
Cold Spring Harbor Laboratory
Mr. DeLay said, "This is the budget the American people voted for when they returned a Republican House, a Republican Senate and a Republican president to the White House last November." Democrats derided the budget as misguided, saying it would slash spending on programs for the most vulnerable members of society, give lavish tax cuts to the wealthiest Americans, force veterans to spend more on health care and deepen the deficit, instead of reducing it, as Republicans contend it will. Although the budget resolution is nonbinding, it is important because it provides an economic blueprint that lawmakers can use to pass specific tax and spending legislation later in the year. For instance, the resolution assumes $106 billion in tax cuts over the next five years, and explicitly directs Congress to enact legislation providing for $70 billion of those cuts. The intent, its authors say, is to extend Mr. Bush's tax cuts on capital gains and dividend income.
The New York Times > Washington > Congress Passes Budget With Cuts in Medicaid and in Taxes
Lilly-Amylin Diabetes Drug Gets FDA Nod:
BioBOOM Op/Ed: We are a big fan of Amylin but can't for the life of us figure out the market reaction (neg) to a second drug approval in 6 weeks for the huge diabetic treatment market. Oh well it's early and like said on an earlier post what diabetic would not want to try this new class which will also help with weight loss. Watch this one grow long term.
Study: California to remain tops in biotech - 2005-04-27
Yahoo! Health News: Cholesterol Drugs May Slow Prostate Cancer:
In 2001, the 10 biotechnology industry leaders posted an 18% increase in product revenue, to $10,992m. This was mainly driven by Amgen and Genentech, generating $4,482m and $1,736m, respectively. Therapeutic proteins are likely to maintain the lead, with forecast revenues of $19,053m in 2007. Amgen's Enbrel will be the top biotech blockbuster, with forecast sales of $3,200m in 2007. Second to therapeutic proteins will be antibodies, forecast to generate $7,635m in 2007. Millennium could replace Celltech in the top 10 biotech firms, with forecast product revenue of $710m in 2007. Over the next five years, Millennium, Scios and Isis will be the three leading emerging players in terms of product sales, with forecast combined revenue of $1,369m."
Celera Donates Gene Data It Once Sold
Huge Eli Lilly deal faced extinction but survived
Beckman Coulter to Buy Agencourt
BioBOOM Op/Ed: Wonder where this puts the Promega relationship?
Yahoo! News - Drug Combo Curbs Nausea of Chemotherapy:
Yahoo! News - U.S. Panel Urges Guidelines for Stem-Cell Research
The New York Times > Health > Mysterious Viruses as Bad as They Get
Monoclonal antibody cures West Nile virus-infected mice
Yahoo! News - Study a Positive Sign on Alzheimer's
Yahoo! News - Outbreak of Angola Virus Under Control
Cheating really does not pay.
View video of the scary lecture here
Read the transcript here
Breakthrough in stem cell research
The New York Times > National > Deadly 1957 Strain of Flu Is Found in Lab-Test Kits
BioBOOM Op/Ed: CAP survey's were never supposed to threaten health but seems this one is. Sure every lab safety officer is hoping their training paid off and staff treated these like "real" patient samples with proper GLP. This is no joke
The University of Leipzig inventors, who spoke at a UK conference in Warwick on Tuesday, said it was 1,000 times more accurate than traditional tests.
The same technology could also be used to find stem cells in blood, they said.
BBC NEWS | Health | Test to spot if cancer has spread
The girl became ill with a fever on the 29th March. Her condition deteriorated rapidly on 7 April, when she was taken to a district referral hospital and then transferred to Kuntha Bopha Hospital in Phnom Penh, where she died. Samples from the girl tested positive for avian influenza H5N1 virus at the Pasteur Institute, Phnom Penh.
WHO | Avian influenza situation in Cambodia - update 15
Mentor Corp. and Inamed Corp.'s, (both of Santa Barbara, CA) silicone breast implants aren't any safer than when U.S. regulators banned earlier devices 13 years ago, patients and their advocates told government advisers today. The testimonies are part of a three day workshop where doctors and scientists will vote on whether the FDA should allow sales of silicone implants. Inamed and Mentor claimed that data they gathered (on a whooping 23 women) showed their silicone implants are safe.
Meanwhile: Mentor shares rose to $34.46 (up by 27 cents) in New York Stock Exchange composite trading. Inamed shares fell $65.02 (down by 57 cents) in Nasdaq Stock Market composite trading. Medicis Pharmaceutical Corp. said 21 March, that it intends to buy Inamed for about $2.8 billion in cash and stock.
"In our estimation, lung cancer is the single biggest opportunity for new cancer therapies," said Lazard analyst Joel Sendek. "The incidence of new lung cancers is over 170,000 a year
Genentech Lung-Cancer Drug Stirs Excitement On Wall Street
Expect controversy today over yesterday's news that the government does not want states to "steer" Medicare recipients towards any specific prescription drug plans. A CMS memorandum released yesterday says that states should not be able to point Medicare patients towards one or two preferred plans, saying that such efforts "may violate federal fraud and abuse laws." Many states have said they want to simplify benefits administration and reduce consumer confusion by screening new prescription drug plans offered under Medicare part D. There had been some speculation that Washington would allow limited state intervention. Yesterday's news, however, suggests that CMS is committed to a free-market model of prescription drug coverage. That is likely to rankle critics who argue the benefit does more for pharma companies than it does for low income Medicare recipients.
San Jose Medical Group told nearly 185,000 current and former patients that their financial and medical records may have been exposed following the theft of computers that contained personal data.
The building was broken into on 28 March. The theft occurred after the San Jose Medical Group had copied patient and financial information from its secured servers to two local PCs. The data, only some of it encrypted, was part of a patient billing project and also part of the medical group's 2004 year-end audit.
Not good news, especially with the rise in identity theft!
Pfizer Inc. suspended sales of Bextra in the United States and the European Union at the request of the Food and Drug Administration and European regulators. The company said that the FDA, in seeking Bextra's withdrawal, cited a risk of serious skin reactions to Bextra on top of the risks shared by other similar drugs.
In addition to the prescription drugs, the FDA asked manufacturers of related over-the-counter painkillers to revise their labels to include information about the risks of cardiovascular incidents and gastrointestinal bleeding.
FDA's public health advisory
MTS was well tolerated in two studies involving patients diagnosed with ADHD. A Phase two trial included 79 patients and a Phase three trial included 238 patients, between 6 -12 years of age. These trials address issues raised by the FDA's review in 2003 and will most likely be included in as part of an amendment to the New Drug Application filed with the FDA.
Robert Strauss, Noven's President, CEO & Chairman, stated: "Today's news is an important step forward in the development of our methylphenidate patch. The next step is preparation of an amendment to the pending New Drug Application, and we expect to be working closely with our partner Shire to achieve that goal."
Matthew Emmens, CEO of Shire, stated: "These results demonstrate that MTS has the potential to provide significant benefits for children with ADHD, especially those that have difficulty taking oral medications and those that find a once-a-day patch more appropriate for their lifestyle. As the ADHD market develops, new choices of treatment are emerging, including specialized delivery systems (such as MTS) to meet the needs of different patients. Shire aims to have a range of medicines in its ADHD portfolio, with ADDERALL XR® being the most prescribed treatment for ADHD in the U.S. If approved, this product will be a strong addition and we look forward to advancing its development further." Shire is expected to release additional details of the trial results as part of an R&D update in May 2005.Shire Pharmaceuticals Group plc is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system, gastrointestinal, and renal diseases. Shire acquired the worldwide sales and marketing rights to MTS from Noven in February 2003.
Noven Pharmaceuticals, Inc. is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products.
Pfizer Inc said today it will sustain long-term growth through investments in innovative current and new medicines from its strong R&D pipeline, while enhancing effectiveness and reducing operating costs.
Two hundred and forty depressed patients were treated with either cognitive therapy, drugs or placebo. Patients in the cognitive therapy group attended 50-minute sessions twice weekly for the first four weeks, once or twice weekly for the middle eight weeks, and then once weekly for the final four weeks. Patients in the drug group received Paxil, Lithium, or Desipramine. After 16 weeks, patients in the the two experimental groups showed improvement at close to the same rate, but patients in the therapy group were less likely to relapse upon followup two years later.
Can you buy stock in group therapy?
These sensors can be applied to many different tasks, ranging from paternity tests and identifying people to detecting genetically modified food, identifying bacterial strains in foodborne illnesses and testing genetic toxicity in new drugs.
Once mass production of the sensors begins, their cost and availability will be similar to that of pregnancy test kits found in pharmacies.
Dr. Ku and his team induced pulmonary hypertension in rats. One group received an extract containing allicin, the control group received boiled garlic (containing no allicin). After three weeks, rats who received boiled garlic developed pulmonary hypertension, while those receiving allicin did not. The team postulates that allicin most likely relaxes the constricted blood vessels, thus reducing damage.
Interestingly, they found allicin had no effect on other types of hypertension, suggesting that allicin has a unique affinity for lung blood vessels. - HC
Yahoo! News - Extra Services May Mean Costlier Medicare
- ► 2013 (23)
- ► 2008 (24)
- ► 2007 (65)
- ► 2006 (77)
- Retroviral resistance gene found - HIV Cure???
- Congress Passes Budget With Cuts in Medicaid and i...
- Lilly-Amylin Diabetes Drug Gets FDA Nod
- Study: California to remain tops in biotech
- Cholesterol Drugs (STATINS) May Slow Prostate Canc...
- Emerging Biotechnology Players: From Innovation to...
- Celera Donates Gene Data It Once Sold
- Eli Lilly & Amylin deal faced extinction but survi...
- Beckman Coulter to Buy Agencourt
- Drug Combo Curbs Nausea of Chemotherapy
- U.S. Panel Urges Guidelines for Stem-Cell Research...
- Mysterious Viruses as Bad as They Get
- Monoclonal antibody cures West Nile virus-infected...
- Gene Therapy a Positive Sign on Alzheimer's
- Outbreak of Angola Virus Under Control
- Contraceptive Sponge to Return to Market
- Biology professor gets even with thief
- Researchers clone cells from existing human stem c...
- Deadly 1957 Strain of Flu Is Found in Lab-Test Kit...
- Test to spot if cancer has spread
- Biopharma giants keep low profile while pushing st...
- WHO: Avian influenza situation in Cambodia - upda...
- Silicone Breast Implants Aren't Safe
- Genentech Lung-Cancer Drug Stirs Excitement On Wal...
- States told to 'back off' on prescription drug ben...
- San Jose Medical Group data stolen
- Pfizer Withdraws Bextra From Market
- Noven and Shire Announce Positive results for Tran...
- Pfizer 2005 profits lower than expected
- Cognitive therapy is as effective as antidepressan...
- Miniaturized DNA chips cuts analysis from days to ...
- Garlic is good for the lungs
- Extra Services Ordered (Lab too) Mean Costlier Me...
- ▼ April (33)